Dublin-headquartered Alkermes is paying $100 million upfront to buy privately-held Rodin and its portfolio of brain permeable histone deacetylase (HDAC) complex-targeting drugs, which it says have ...

LBH589 is a novel pan-histone deacetylase (HDAC) inhibitor that has potent antitumor ... and T-cell (major histocompatibility complex-restricted) activation in innate and adaptive immunity.